Medi Futures (CEO Kim Ji-min) of Ultrasonic Biomedical Company made an announcement on the 24th that it has attracted $0.88M USD (1 billion won) in investment from Mega Investment.
Based on ultrasonic platform technology, Medi Futures commercialized ultrasound endoscopic disk surgical instruments and ultrasound stem cell separator that doesn’t need enzyme. Recently, it has developed and exported medical suture named Barbed Suture, which has a delicate shape and is very strong. More than 80 percent of sales are occurring overseas.
“Based on ultrasonic medical technology, Medi-Futures has recognized as a competitive edge that it is highly likely to expand to advanced countries in the U.S. and Europe in general medical fields as well as in the field of aesthetic technologies.”
Shin Na-ri, chief judge of Mega investment
Mega Investment is a new technology financial company that was established in 2012. It is actively investing in education, software and IT. Investments such as PeopleBio, a diagnosis company for Alzheimer’s disease, and Speclipse, a technology company for skin cancer, are expanding its investment into biomedical fields. Recently, it was selected as the operator of the Korea Growth Finance Youth Job Fund, which will be created at $44.2M USD (50 billion won).
“Mega investment is an investment company that has an understanding of biomedical technologies and has excellent expert judges. We will closely consult each other as a strategic advisor for the growth of Medi-Futures in the future,”
Kim Ji-min, CEO of Medi-Futures
